Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 3/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.40 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL20580864 | 1.00 | LTA4H (0.43) | LTA4HALPIPKMPTGS1XIAP | |
| SCHEMBL2585866 | 0.91 | EPHX1 (0.47) | LTA4HEPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29359776 | 0.91 | EPHX1 (0.47) | LTA4HEPHX1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL4087778 | 0.90 | EPHX1 (0.46) | LTA4HEPHX1SLC1A3SLC1A2SLC1A1 | |
| Pabetan SCHEMBL29894618 | 0.87 | NPY4R (0.46) | EPHX1TRHDENPY4RNPY1RNPY2R | |
| Pabetan SCHEMBL21571465 | 0.87 | NPY4R (0.46) | EPHX1TRHDENPY4RNPY1RNPY2R | |
| Pabetan SCHEMBL14928984 | 0.87 | NPY4R (0.46) | EPHX1TRHDENPY4RNPY1RNPY2R | |
| Pabetan SCHEMBL4546522 | 0.87 | NPY4R (0.46) | EPHX1TRHDENPY4RNPY1RNPY2R | |
| Arginine SCHEMBL29067351 | 0.85 | ALPI (0.46) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Arginine SCHEMBL29094092 | 0.84 | ALPI (0.45) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023694-A1 | BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA | TANDON, VIBHA (IN) | 2019-01-24 | — | — | US | claimed |
| WO-2017125944-A1 | BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA | JAWAHARLAL NEHRU UNIVERSITY (JNU) (IN) | 2017-07-27 | — | — | WO | claimed |
| US-11951154-B2 | Compositions and methods for cell delivery | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230407243-A1 | GENETIC PLATFORM TO INVESTIGATE THE FUNCTIONS OF BACTERIAL DRUG EFFLUX PUMPS | UNIVERSITY OF GUELPH (CA) | 2023-12-21 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20230174978-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230054672-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230024896-A1 | COMPOSITIONS AND METHODS FOR CELL DELIVERY | PIONEERING MEDICINES 08- B, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11382950-B2 | Compositions and methods for cell delivery | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11312955-B2 | Methods and compositions for modulating gene expression | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220023270-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2018220365-A1 | ANTIBIOTIC RESISTANCE BREAKERS | KING'S COLLEGE LONDON (GB) | 2018-12-06 | — | — | WO | disclosed |
| EP-3386985-A1 | PBD ANTIBACTERIAL AGENTS | Kings College London (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-20180179525-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2018049077-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049075-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049079-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049073-A1 | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION | FLAGSHIP PIONEERING, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017125944-A1 | BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA | JAWAHARLAL NEHRU UNIVERSITY (JNU) (IN) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017098257-A1 | PBD ANTIBACTERIAL AGENTS | KING'S COLLEGE LONDON (GB) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | LTA4H 1137/4885ALPI 511/4885PKM 3042/4885 |
| US-20220023270-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CLPP, SPOUT1, MRPL21 | LTA4H 1179/4885ALPI 247/4885PKM 2549/4885 |
| US-20190023694-A1 | BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA | TOP2B, TOP2A, TOP1 | LTA4H 4391/4885ALPI 435/4885PKM 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.